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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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Despite the disappointing clinical trial results reported last week
by Roche and Wave Life Sciences, Huntington’s disease drug
researchers see an upside: they are using the data collected to
achieve new insights, offering renewed hope of effective
treatments.

► March (2)
► February (2)
► 2020 (16)
► 2019 (19)
► 2018 (16)

The news of these setbacks produced one of the most
heartbreaking moments of the last several decades for the HD
community and researchers.
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“That kind of news, I hope it’s okay to say: it sucks!” said Robert
Pacifici, Ph.D., the chief scientific officer for CHDI Foundation,
Inc., of the Roche and Wave trial data. “All of us who hold out so
much hope and recognize that there are so many families who so
desperately are waiting for much needed relief and therapies – it
knocks the wind out of you.”
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The companies made their first formal scientific presentations of
their data at the start of the CHDI-sponsored 16th Annual HD
Therapeutics Conference, held virtually from April 27-29. A
nonprofit virtual biotech, CHDI focuses solely on developing
Huntington’s therapies.
Roche confirmed that its drug tominersen failed to alleviate
symptoms in its Phase 3 clinical trial; patients receiving the
highest of two possible doses may have done even slightly worse
than those on placebo. Two early-stage Wave trials failed to meet
the goal of reducing the amount of mutant huntingtin protein in the
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trial participants – an objective already achieved by Roche in an
earlier tominersen trial. (Click here to read more.)
Dr. Pacifici offered his assessment of the Roche and Wave data
and the state of HD drug research in a wide-ranging, 46-minute
Zoom interview with me after the close of the event.
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Dr. Robert Pacifici moderates panel discussion of huntingtin-lowering clinical
trial results with Dr. Vissia Viglietta of Wave Life Sciences and Dr. Scott Schobel
of Roche (screenshot by Gene Veritas, aka Kenneth P. Serbin)

Gaining perspective
“My reaction though, now that I’ve come back down to earth, is
really not one of surprise,” Dr. Pacifici said. “Drug discovery, as
we’ve discussed many times, is a really tough business. The
probability of success on any given endeavor is incredibly low.”
Dr. Pacifici used a baseball metaphor to explain: “How often does
the first batter get up to the plate and hit a grand slam home run? A
grand slam, never, because you need to load up the bases with
three people. Even a home run is incredibly rare.”
The “name of the game” in discovering effective treatments is to
carry out as many trials as necessary, “doing it well, failing, but
making it a good failure that we can learn from so that subsequent
efforts have a much higher chance of success,” Dr. Pacifici
explained. “And we continue to snowball and build on that so that
we can learn the things to do better, the things that we can do
differently, or the things that we should stop doing altogether
because we now have confirmed that those are not viable lines of
investigation.”
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The accumulation of experience through research and clinical
trials, including the crucial participation of patient volunteers, has
produced “an incredibly positive thing,” Dr. Pacifici observed.
“Look at how the field has matured,” he said. In the past, scientists
would have kept a trial running for three years, waiting for patient
improvement, only to discover that “the drug really didn’t even
have a chance of working” because it hadn’t done what it was
“tasked with doing, which is lowering huntingtin levels.”
Now the process is moving “faster” and is “better informed,” Dr.
Pacifici said.
Watch the entirety of my interview with Dr. Pacifici in the video
below.

Huntington's disease drug research now a 'mature field'
from Gene Veritas

46:43

Huntington's disease drug research now a 'mature field' from Gene Veritas on
Vimeo.

Huntingtin lowering still in the running
Dr. Pacifici commented on the critical topic of lowering (reducing)
the mutant huntingtin protein, the first strategy aimed at HD’s
genetic cause. Scientists believe that the mutant protein is a main
driver of the disease. In mouse studies, lowering that protein led to
a disappearance of symptoms, and, beginning with the Roche trial,
researchers have sought to achieve similar results in humans.
Thus, until now, lowering mutant huntingtin has been seen as the
potentially most promising path to a treatment.
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Both Roche and Wave used a type of drug known as an antisense
oligonucleotide (ASO), an artificial strand of DNA. Other firms
and labs are also investigating ASOs.
“When two of those things don’t move forward simultaneously,
it’s perfectly reasonable to ask the question, ‘Well, is this one of
those times where we’ve learned that this approach is not going to
work?’” Dr. Pacifici asked. “I can say unequivocally that that’s not
yet the case. There are just too many things that factor into how a
drug needs to do its job that remain unanswered.”
He said that possible key factors affecting the outcomes of the
Roche and Wave trials include the stage of disease of the
participants, the concentration of the drug tested, and the proper
distribution of the drug within the brain. The particular
characteristics of the drugs selected could have also impacted the
outcome, he added.
Another possible explanation involves the design of the trials, the
techniques for measuring patient response, and biomarkers (signs
of disease and a drug’s effects).
In addition, even though Roche’s tominersen reduced the level of
mutant huntingtin protein in trial volunteers’ cerebrospinal fluid,
researchers still do not know whether the samples of protein
actually came from the brain and, if so, cells relevant to HD, Dr.
Pacifici cautioned. Scientists also lack other critical details about
those samples; for example, they could be fragments, he said.
Crucially, the “interim analysis” of the Roche data at the
Therapeutics conference did not demonstrate whether lowering
huntingtin can help people feel, function, or survive better, Dr.
Pacifici observed.
Even a “whisper of efficacy” would have validated the huntingtinlowering approach and “prepared the path for subsequent trials
with gusto and confidence,” he continued, adding, however, that
“the opposite is not true. We still have great hopes that this is a
viable mechanism of action.”
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Wave plans to start a trial of a third ASO later this year. Roche has
also stated that it will continue to explore drugs for HD.
Exploring other avenues
Because the effectiveness of huntingtin-lowering remains an open
question for the field, Dr. Pacifici renewed his call to redouble and
diversify drug-hunting efforts.
Dr. Pacifici noted that other potential huntingtin-lowering
approaches are in the works using non-ASO compounds, while
others propose different methods of delivery, including a pill. In
the Roche and Wave trials, participants received the drug via
spinal tap.
“If we were in a fantasy world of the 20th new treatment for
Huntington’s coming, you would worry about things like
convenience: ‘I’d like to have a pill instead of an injection,’” Dr.
Pacifici said. “‘I’d like to have a pill I can take once a day. I’d like
to have a small pill that’s easy to swallow.’”
However, Dr. Pacifici observed, “we’re not at that stage yet.” Even
so, “very critical advantages” exist in exploring different modes of
delivery, he said.
Indeed, another possibility emerged at the conference. A scientist
from pharmaceutical giant Novartis presented research on its drug
branaplam, a pill used to treat spinal muscular atrophy (SMA),
which causes severe muscle weakness in children. Novartis
researchers discovered that Branaplam also reduced the amount of
the huntingtin protein in a study of SMA patients. Novartis plans a
trial of branaplam in HD patients, with details expected in the
coming weeks and over the summer (click here to read more).
Like other so-called small-molecule drugs, branaplam becomes
distributed very evenly across the whole body, including the brain,
whereas a drug like an ASO tends to concentrate where it is
administered, Dr. Pacifici explained. He added that small-molecule
drugs can be dosed “creatively” – for example, weekly instead of
curehd.blogspot.com/2021/05/the-first-at-bat-is-never-grand-slam.html
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daily – to maximize the “beneficial effect” and allow the person a
rest from the drug.
(I will explore the quest to develop this type of HD drug in a
future article.)

Dr. Rajeev Sivasankaran of Novartis presents data demonstrating the effect of the
drug branaplam on huntingtin RNA in a study of spinal muscular atrophy patients
(screenshot by Gene Veritas).

Sharing knowledge rises all boats
Dr. Pacifici emphasized that success in the fight against HD
ultimately depends on the sharing of scientific information – even
negative research results that private companies are loathe to
reveal to protect their egos and their stock prices.
He cited the presentation by featured speaker Aled Edwards,
Ph.D., the founder and CEO of the Structural Genomix
Consortium, which practices and advocates for open sharing of
scientific information, particularly as it applies to protein science,
chemical biology and drug discovery. Dr. Edwards spoke on “HD
drug discovery in the public domain – a model for CHDI.”
“I think the HD field will benefit by everybody realizing how
difficult this problem is,” Dr. Pacifici concluded. “It’s not giving
up a competitive advantage by being transparent about what
happened. It’s sharing data. That knowledge rises all boats.
Everybody needs to know about these things.”
Sharing of data and other knowledge has also been one of CHDI’s
trademarks as a nonprofit. Dr. Pacifici pointed to specifics:
curehd.blogspot.com/2021/05/the-first-at-bat-is-never-grand-slam.html
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knowledge about the disease, potential treatments, biomarkers, and
clinical outcome measures (the techniques for measuring patient
response).
With such sharing, he asserted, everybody will have an increased
chance of success.
Refusing to do so will “doom us to the same failure we see in
other neurodegenerative fields that have outspent us and been at
this a lot longer than we have.”
Posted by Gene Veritas at 4:31 PM
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